Chemo-embolization in the treatment of hepatocellular carcinoma: should we switch to charged particles in our countries? About 102 procedures of a North African radiology center

##plugins.themes.academic_pro.article.sidebar##

Published Oct 10, 2018
Download
pdf
Vol. 96 No. 7 (2018): Issue Jul 2018

##plugins.themes.academic_pro.article.main##

Leila Ben Farhat Charrada
Hayfa Romdhane
Service de Gastro-entérologie A. Hôpital la Rabta. Tunis
Zeineb Mzoughi
Meriem Cheikh
Ghofrane Talbi
Ines Marzouk

Abstract

Background: Hepatocellular carcinoma (HCC) is a public health problem in african countries. The chemoembolization (CE) could represent the only therapeutic strategy. Two methods can be proposed: charged microparticles and lipiodol chemoembolization.
The purpose of this study was to compare results, morbidity and survival between charged microparticles and lipiodol chemoembolization.
Methods : A 5 years retrospective, study was conducted including 62 patients with HCC treated by chemioembolization. The efficacy of the treatment was evaluated for patients by performing a computed tomography four to six weeks after the act. We used « European Association for Study of the Liver » criteria to evaluate the therapeutic outcome.
Results : A total of 102 sessions of chemoembolization were performed. This was a with charged microparticles in 70 cases (68.6%) and lipiodol chemoembolization in 32 cases (31.3 %). The difference was not significant between the two CE techniques (lipiodol and charged microparticles) in terms of complete and objective response and complications. The mean survival rate was 30 months ± 4 for all techniques combined, with no statistically significant difference in terms of survival time without recurrence between the two chemoembolization techniques.
Conclusion:
The efficacy, morbidity and survival of the two CE techniques to lipiodol or microfilled particles are comparable. The selectivity of the technique is to be taken into consideration.
For economic health purposes, the CE lipiodolée appears to be more adapted to the context of the developing African countries.

Keywords:

Hepatocellular carcinoma, chemoembolization, imaging, survival rate

##plugins.themes.academic_pro.article.details##

References

  1. Ntagirabiri R, Munezero B, Kaze H, Ndirahisha E, Manirakiza S. Incidence of hepatocellular carcinoma in chronic infection with hepatitis B. Pan Afr Med J 2015 Feb 23;20:167.
  2. Nikièma Z, Sawadogo A, Kylem CG, Cissé R. Hepatocellular carcinoma in rural Burkina Faso Africa : contribution of ultrasound, about 58 cases Pan Afr Med J 2010 ;7 :10
  3. Doyon D MA, Jourde AN et al. L'embolisation artérielle hépatique dans les tumeurs malignes du foie. Ann Radiol 1974;17:593-603.
  4. Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54(4):695-704.
  5. Syha R, Ketelsen D, Heller S, Schmehl J, Mangold S, Heuschmid M, et al. Hepatocellular carcinoma: initial tumour response after short-term and long-interval chemoembolization with drug-eluting beads using modified RECIST. Eur J Gastroen Hepat. 2012;24(11):1325-32.
  6. Chung JW, Park JH, Han JK, Choi BI, Han MC, Lee HS, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology. 1996;198(1):33-40.
  7. Russell JS, Sawhney R, Monto A, Nanavati S, Davoren JB, Aslam R, et al. Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center. Am J Surg. 2010;200(5):659-64.
  8. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J of Radiol. 2009;72(3):505-16.
  9. Kim JW, Shin SS, Kim JK, Choi SK, Heo SH, Lim HS, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection. Korean J Radiol. 2013;14(4):626-35.
  10. Gobel T, Blondin D, Kolligs F, Bolke E, Erhardt A. Current therapy of hepatocellular carcinoma with special consideration of new and multimodal treatment concepts. Deutsche medizinische Wochenschrift. 2013;138(27):1425-30.
  11. Van Beers B, Roche A, Cauquil P, Jamart J, Pariente D, Ajavon Y. Transcatheter arterial chemotherapy using doxorubicin, iodized oil and Gelfoam embolization in hepatocellular carcinoma. Acta radiologica. 1989;30(4):415-8.
  12. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol. 2010;101(6):476-80.
  13. Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57(6):1244-50.
  14. Tsochatzis E, Meyer T, Marelli L, Burroughs AK. Which transarterial therapy is best for hepatocellular carcinoma?--the evidence to date. Journal of hepatology. 2010;53(3):588.
  15. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. British journal of cancer. 2014;111(2):255-64.
  16. Monier A, Guiu B, Duran R, Aho S, Bize P, Deltenre P, et al. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. Euro radiology. 2016;95(12):450-8.
  17. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. British J cancer. 2014;111(2):255-64.
  18. Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. Tech Vasc Interv Radiol. 2011;22(11):1545-52.
  19. Shimohira M, Ogino H, Kawai T, Kushita A, Watanabe M, Kawaguchi T, et al. Use of the triaxial microcatheter method in super-selective transcatheter arterial chemoembolisation for hepatocellular carcinoma. Br J Radiol. 2011;84(998):184-7.
  20. Matsui O, Miyayama S, Sanada J, Kobayashi S, Khoda W, Minami T, et al. Interventional oncology: new options for interstitial treatments and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome. J Hepatobiliary Pancreat Sci. 2010;17(4):407-9.
  21. She HL, Burgmans MC, Coenraad M, Saraqueta AF. Erratum to: In Vivo Proof of Superselective Transarterial Chemoembolization with 40-mum Drug-Eluting Beads in a Patient with Hepatocellular Carcinoma.J Vasc Interv Radiol. 2015;38(5):1380.
  22. C.Pelletier, G.Roche, A.Ink, O.Anciaux, M. L.Derhy S.Rougier,P.Lenoir,C.Attali,P.Etienne, J. P. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990;11(2):181-4.
  23. Recchia F, Passalacqua G, Filauri P, Doddi M, Boscarato P, Candeloro G, et al. Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicineluting beads compared with lipiodol. Oncol Rep. 2012;27(5):1377-83.